Description: This cisplatin-resistant cell line has been developed by exposure of the parent L929 murine fibroblast cell line (ECACC catalogue no. 85011425) to increasing concentrations of cisplatin in vitro. L929/R cells can be used in the development of novel anti-cancer treatments. The parent cell line L929 was derived from normal subcutaneous areolar adipose tissue.

Also Known As:

Species: Mouse

Tissue: Adipose

Growth Properties: Adherent

Morphology: Fibroblast

Growth Medium: RPMI 1640 + 2mM L-Glutamine + 10% Foetal Bovine Serum (FBS) + 0.26µM Cisplatin.

Subculturing Procedure: Split sub-confluent cultures (70-80%) 1:5 to 1:50 i.e. seeding at 1-2×10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 2% CO2; 37°C.

Release Conditions: No

Depositor: Dr. Stephen Merry, Faculty of Health Sciences, Staffordshire University, Stoke-on-Trent, UK

Originator: Yes

References: Wedgwood JL, Kresinski RA, Merry S, Platt AW. 2003 The preparation, characterisation and in vitro cytotoxicity of potentially chemotherapeutic heterobimetallic complexes containing early and late transition metals.J Inorg Biochem. 95(2-3):149-56.PMID: 12763659.

Hyperlink to ECACC Cell Line Data Sheet: 04102001